ADXN Addex Therapeutics Ltd
$2.99▲ +3.10%
Healthcare
Other
Volume 439
Avg Volume (10D) 7.4K
Key Metrics & Fundamentals
Market Cap
$5.24M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.56 - 10.43
% vs 50 MA
-13.79%
% vs 200 MA
-49.16%
RSI-14
45.5
MACD Histogram
+0.0500
Beta (1Y vs SPY)
1.25
Free Cash Flow
-$468,260
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.72M
COGS
–
Operating Exp
$645,352
Operating Income
-$645,352
EBIT
-$645,352
Pretax Income
-$1.74M
Net Income
-$1.74M
EPS (Diluted)
-1.20
Price & Volume History
Loading chart…
Recent News
Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
GlobeNewswire · Oct 8, 2026 1:00 AM ET
Addex Therapeutics Announces Executive Management Changes
GlobeNewswire · Oct 2, 2026 1:00 AM ET
Addex Therapeutics Ltd (ADXN) (Q2 2026) Earnings Call Highlights: Regained GABAB PAM Rights and ...
GuruFocus.com · Sep 30, 2026 9:00 PM ET
Addex (ADXN) Q2 2026 Earnings Call Transcript
Motley Fool · Sep 28, 2026 10:43 PM ET
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
GlobeNewswire · Sep 28, 2026 1:00 AM ET
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
GlobeNewswire · Sep 25, 2026 1:00 AM ET
Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
GlobeNewswire · Sep 24, 2026 1:00 AM ET
ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
GlobeNewswire · Aug 26, 2026 1:00 AM ET
Financial Overview - Income Statement
Quarterly
Dec 2025
See ADXN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.